Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioReliance, a provider of contract services to the pharmaceutical and biopharmaceutical industries, has signed an agreement with Provecs Medical, a developer of immunotherapies against cancer, for production of investigational quantities of Immunalon, a novel therapeutic agent based on an adenovirus vector that stimulates an immunological response against tumor cells.
Subscribe to our email newsletter
Frank Schnieders, CEO of Provecs, said: “With the conclusion of this agreement with BioReliance, we have moved significantly closer to the commencement of clinical trials with Immunalon. In animal studies, it has been shown capable of stimulating a strong immunological response to tumor cells.
“It holds the possibility of causing the immune system to attack and destroy tumors and their metastases. We selected BioReliance to manufacture investigational quantities of Immunalon because of their reputation for quality and reliability.”